London, UK, 19 July 2018: CN Bio Innovations Limited today announced that its Board of Directors has accepted the resignation of Dr Emma Sceats as CEO and Director of CN Bio and appointed Dr David Hughes as Chief Executive Officer effective immediately. Dr Hughes has been centrally involved in the licensing and commercialisation of CN… Read more »
News
Filter: Press Releases
Posted
CN Bio launches PhysioMimix benchtop Human-Body-on-a-Chip device
London, UK, 23 May 2018: CN Bio Innovations Limited today launched PhysioMimix, a printer-sized device which allows scientist to conduct organ-on-chip studies in their own labs, testing new drugs and chemicals on living human organ models. Dr Emma Sceats, CEO of CN Bio Innovations, said: “We can all understand the value of predicting how a… Read more »
Posted
CN Bio and MIT announce 10 Organ-On-Chip Platform: Nature Scientific Reports
Organ-on-Chip specialist CN Bio’s microfluidic platform for improving drug evaluation has taken a significant step forward. CN Bio’s partners at MIT today published details of the platform which successfully connects engineered tissues from up to 10 organs, accurately replicating human organ interactions for weeks at a time and allowing them to measure the effects of… Read more »
Posted
CN Bio Innovations announces research collaboration with AstraZeneca to validate a new in vitro tool to predict optimised drug dosing regimens for multi-drug therapies
London, UK, November 1 2017: Organ-on-a-Chip specialist CN Bio Innovations Limited announces a research collaboration with global biopharmaceutical company AstraZeneca to validate a new in vitro research tool that enables the high throughput evaluation of multi-drug dosing regimens. Under the collaboration, CN Bio will leverage intellectual property and technologies recently licensed by the company from… Read more »
Posted
FDA signs collaborative agreement with CN Bio Innovations to use Organs-on-Chips to improve drug development and evaluation
London, UK, October 26 2017: CN Bio Innovations Limited announced today that it has entered into a Research Collaboration Agreement with the US Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research. FDA and CN Bio will collaborate to characterize the performance of CN Bio’s Organs-on-Chips as a platform for potential use in… Read more »
Posted
Innovate UK awards grant to CN Bio Innovations and AstraZeneca to use Organs-on-Chips to evaluate the use of existing drugs to treat fatty liver disease
London, UK, October 11 2017: Organ-on-a-Chip specialist CN Bio Innovations Limited announces that Innovate UK has awarded the company a £670,000 grant co-funded by the newly created Industrial Strategy Challenge Fund. Under the award, CN Bio will collaborate with global biopharmaceutical company AstraZeneca to combine Organ-on-a-Chip models of fatty liver disease and non-alcoholic steatohepatitis (NASH)… Read more »
Posted
CN Bio Innovations announces licence of platform microfluidics technologies from Vanderbilt University
London, UK, October 10 2017: CN Bio Innovations Limited announces that it has licensed from Vanderbilt University three patents and applications, and software, covering microfluidics technologies relevant to the company’s Organs-on-Chips products and IP portfolio. The agreement includes exclusive rights to applications claiming priority from US 15/191,092, as well as non-exclusive rights to US 9,618,129… Read more »
Posted
CN Bio Innovations announces license of worldwide rights to Hepatitis B programme from Bristol-Myers Squibb
London, UK, April 5 2017: CN Bio Innovations Limited announces that it has licensed from Bristol-Myers Squibb Company a Hepatitis B drug discovery programme comprising several series of small molecule antiviral compounds. The exclusive agreement enables CN Bio to undertake discovery, development and commercialisation of the antiviral compounds to create a combination treatment for chronic Hepatitis… Read more »
Posted
Dr Emma Sceats of organ-on-a-chip firm CN Bio Innovations wins Innovate UK’s infocus Women in Innovation award
Welwyn Garden City, UK- 15th November 2016: Following a nationwide competition, CEO of London bioengineering firm CN Bio Innovations Dr Emma Sceats has been named as a winner of Innovate UK’s infocus Women in Innovation award. The awards will be celebrated as part of the Lloyds National Business Awards in London tonight. Innovate UK’s infocus… Read more »
Posted
CN Bio Innovations announces research collaboration with Alnylam
CN Bio Innovations, an expert in developing human organ-on-a-chip platforms to test and develop therapeutics for liver diseases and infection, is pleased to announce the commencement of a research collaboration with Alnylam Pharmaceuticals. Research relevant to the advancement of Alnylam’s RNAi therapeutics will be performed using CN Bio’s human liver-on-a-chip platform, LiverChip.
Posted
CN Bio announces research collaboration with gene silencing specialist Benitec Biopharma
CN Bio Innovations, an expert in developing human biomimetic platforms to test and develop therapeutics for liver diseases and infection, is pleased to announce that it has embarked on a research collaboration with RNAi-based therapeutics company, Benitec Biopharma Limited (ASX:BLT). Read full press release
Posted
CN Bio announces opening of new Biosafety Level 3 facility
CN Bio Innovations Ltd (CN Bio), an expert in developing human biomimetic platforms to test and develop therapeutics for serious diseases, announced today the opening of a new facility, including state-of-the-art Biosafety level 3 (BSL-3) laboratories, in Welwyn Garden City, UK. The BSL-3 laboratories will be dedicated to research, development and drug discovery alliance programmes… Read more »
Posted
Imperial College London to present first public HBV data from CN Bio in vitro liver model
CN Bio Innovations Ltd (CN Bio), an expert in developing human biomimetic platforms to test and develop therapeutics for serious diseases, has announced that data from its research collaboration with Imperial College London, where the team are analysing a novel human, full-viral-lifecycle model of Hepatitis B, will be the subject of oral and poster presentations… Read more »
Posted
CN Bio Innovations marks World Hepatitis Day by signing research agreement with Imperial College London
Collaboration will develop and further validate CN Bio’s in vitro model of Hepatitis B liver infection Oxford, UK, 28 July 2014: CN Bio Innovations Ltd (CN Bio), an expert in developing leading edge human biomimetic platforms to test and develop therapeutics for serious diseases, announced today that it has signed a research agreement with Imperial… Read more »
Posted
Zyoxel Ltd to become CN Bio Innovations Ltd
Zyoxel, an expert in advanced in vitro 3D liver models for drug discovery and drug testing, has today announced it is changing its name to CN Bio Innovations Ltd (CNBIO). The move is part of a strategic rebrand designed to closer align the organisation with its Hong Kong-based holding company, CN Innovations Holdings Limited (CNI)…. Read more »
Update: News
- Press releases
- 19 July 2018
- CN Bio Innovations’ Board names David Hughes as next Chief Executive Officer
- Business
- 19 June 2018
- Organ-on-Chip Webinar: Improving Preclinical Studies for Faster Drug Development
Meet Us: Events
- 9-10 Oct 2018
- ELRIG Drug Discovery 2018
- London, UK
- 31 OCT - 1 NOV 2018
- Lab Innovation 2018
- Birmingham, UK
- 5 - 7 NOV 2018
- BioEurope
- Copenhagen, Denmark